FDA Approves Jazz's Zanidatamab for HER2+ Biliary Cancer with 52% Response Rate

Nov 21, 2024, 12:36 AM

The U.S. Food and Drug Administration (FDA) has approved a new drug, zanidatamab-hrii (Ziihera), developed by Jazz Pharmaceuticals, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval marks a significant advancement in the treatment of this specific cancer type, with the drug showing a 52% response rate and a median duration of response of 14.9 months.